Investor and Industry Conference Apperances These next couple of days are going to be exciting for TapImmune. If you did not have the opportunity to read our press release that was published last Wednesday, our CEO and COO will be speaking at two different conferences. Chairman and CEO, Dr. Glynn Wilson, will be presenting today…
Dr. Glynn Wilson, Chairman and CEO of TapImmune, will provide an overview of the company’s business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform during his presentation at the 5th Annual Cancer Biopartnering & Investment Forum
TapImmune Inc. will likely have no profit or revenue for the foreseeable future. But the Jacksonville-based immuno-oncology company is taking steps to attract attention on Wall Street.
The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $3.7 million to conduct a Phase 2 trial of TapImmune’s HER21-targeted T-cell vaccine in women with the breast cancer known as ductal carcinoma in situ (DCIS).
TapImmune today provided its first quarterly business update, following the company’s uplisting to The NASDAQ Capital Market in the fourth quarter 2016. A public conference call and live audio webcast is scheduled for today at 4:30 pm ET.
TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer
TapImmune announced that its collaborators at the Mayo Clinic, recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on TapImmune’s HER2/neu-targeted T-cell vaccine that will enroll women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS).
TapImmune today announced that the Company will host a conference call and live audio webcast on Tuesday, March 14, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the fourth quarter and year end 2016.
A Jacksonville doctor is working on a vaccine that would fight off several types of cancer. He said he’s about halfway through the process before it would get to the market. A vaccine called TPIV 200 would prevent breast, ovarian and some lung cancers, and it is being created in a Mayo Clinic lab by Dr. Keith Knutson.
A Jacksonville doctor is working on a vaccine that would fight off several types of cancer. He said he’s about halfway through the process before it would get to the market. “If it works, that would be a good thing for all us women,” Jacksonville resident Lakysha Tyler said.
A professor in Jacksonville said he’s closer to his dream of a vaccine to prevent breast, ovarian and some types of lung cancer. According to a FOX 13 report, immunology professor Dr. Keith Knutson said his dream would be to develop a vaccine to prevent cancer development.